Q4 FY2026 EarningsQ4 FY26 results beat consensus across the top and bottom lines: revenue was $321.2M vs. $314.5M expected, and adjusted EPS reached $0.52, slightly ahead of the $0.519 mean. The Diagnostics and Spatial Biology segment showed strong momentum with 8% organic growth, while the Protein Sciences segment remained steady with 1% organic growth. Operating performance was bolstered by profitability initiatives and divestitures, maintaining adjusted operating margins at 32.2% amid a pending $11.3 billion acquisition by Merck KGaA.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Bio-Techne(TECH) the Revenue is 321.19 M (+1.33%), Beat estimate;the EBIT is 103.36 M (+2.01%), Miss estimate;the EPS is 0.35 (+418.2%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.32B1.33%
0.31B0.77%
+0.01B2.10%
EBITMiss expectations
0.10B2.01%
0.10B3.58%
-0.00B1.57%
EPSMiss expectations
0.35418.18%
0.3525420.45%
-0.00252.27%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf